Listed by the USPTO as LEVERETT, MARY CHANG
Tech Center 2100 • Art Units: 1672 1681 1682 1687 1794 2123
This examiner grants 59% of resolved cases
LEVERETT, MARY CHANG is a USPTO patent examiner in Tech Center 2100 and Art Unit 1672. The profile covers 101 resolved cases, with an allowance rate of 59.4% and a median of 1518 days to allowance. Interviews are associated with a 23.5% lift, making interview preparation a potentially useful prosecution consideration in this docket.
The principal companies represented include 10x Genomics Inc., Monsanto Technology LLC, and JVCKENWOOD Corporation. The leading firms are AMIN, TUROCY & WATSON, LLP, BALLARD SPAHR LLP, and DLA Piper LLP (US) Boston. Applicants in this profile may benefit from reviewing interview practice alongside claim strategy, particularly where prosecution timing is important.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17898240 | SYSTEMS AND METHODS FOR IDENTIFYING ADAPTIVE IMMUNE CELL CLONOTYPES | Non-Final OA | 10x Genomics, Inc. |
| 18358001 | GENE MODEL FOR JUDGING PROGNOSIS OF HEPATOCELLULAR CARCINOMA PATIENTS, CONSTRUCTION METHOD AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18069110 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18281085 | METHODS FOR RECONSTITUTING T CELL SELECTION AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18134518 | Methods And Systems For Identifying Hybrids For Use In Plant Breeding | Non-Final OA | Monsanto Technology LLC |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | Non-Final OA | UMC Utrecht Holding B.V. |
| 17899470 | SYSTEMS AND METHODS FOR CLASSIFYING AND TREATING HOMOLOGOUS REPAIR DEFICIENCY CANCERS | Final Rejection | Foundation Medicine, Inc. |
| 18174468 | CALIBRATION SEQUENCES FOR NUCLEOTIDE SEQUENCING | Non-Final OA | Illumina, Inc. |
| 18080620 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Non-Final OA | SEQUENOM, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.4% of resolved applications examined by Mary Chang Leverett were allowed (101 resolved cases), compared with 38.3% across Art Unit 1672 over the last five years.
This examiner's interview lift is +23.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Mary Chang Leverett took 1,518 days on average from filing to allowance.
Mary Chang Leverett examines applications in Art Unit 1672 in Tech Center 2100 (Computing & Software).
